Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of funding the cost of medicines regulation undertaken by the Medicines and Healthcare products Regulatory Agency.

The Medicines and Healthcare products Regulatory Agency (MHRA) is a largely fee charging regulator with approximately three quarters of its income derived from fees levied on applicants. This is a standard form of cost recovery for regulators worldwide. The MHRA has recently concluded a public consultation on its statutory fees to ensure all costs involved in delivery are recovered, which concluded on 23 November 2022.